+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies



Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies



Aids 14(9): 1195-1201



Objectives: To assess the role of resistance mutations in subjects experiencing virological failure on zidovudine (ZDV) and lamivudine (3TC) combined with a protease inhibitor (PI) to those failing on ZDV/3TC alone. Design and methods: Samples were obtained from previously antiretroviral therapy-naive subjects enrolled into two studies, AVANTI 2 and AVANTI 3. Subjects were randomized to receive either: ZDV/3TC or ZDV/3TC plus indinavir (IDV) for 52 weeks (AVANTI 2), and ZDV/3TC or ZDV/3TC and nelfinavir (NFV) for 28 weeks (AVANTI 3). Emergence of viral resistance mutations was monitored by population sequencing and phenotypic resistance was determined by the recombinant virus assay. Results: Genotypic data were obtained for subjects with plasma HIV-1 RNA > 400 copies/ml. In AVANTI 2, ZDV mutations were detected in 27% of ZDV/3TC-treated patients at week 52, but were absent in subjects treated with ZDV/3TC/IDV. No subjects from either arm of AVANTI 3 developed ZDV resistance mutations at week 28. The M184V mutation developed in most ZDV/3TC-treated subjects from both studies. The presence of M184V was, however, associated with significantly lower plasma viral RNA levels when compared with values obtained before initiation of treatment. There was a high frequency (4 of 11) of the protease L10F substitution in ZDV/3TC/IDV-treated patients that was associated virological failure but did not result in phenotypic resistance to any of the PIs tested. Conclusions: ZDV mutations were not detected in ZDV/3TC/PI-treated patients and they developed slowly in those treated with ZDV/3TC. Few protease mutations known to confer phenotypic PI resistance developed in the ZDV/3TC/PI arms of either study. The low prevalence of ZDV and PI mutations is encouraging regarding the future treatment options of these patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010112864

Download citation: RISBibTeXText

PMID: 10894284

DOI: 10.1097/00002030-200006160-00017


Related references

AVA, ACAC and PIAS. Australian Veterinary Journal 78(10): 673, 2000

AVA: visual analysis of gene expression microarray data. Bioinformatics 19(2): 293-294, 2003

AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group. Antiviral Therapy 4(2): 79-86, 1999

Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 123(3): 335-343, 1998

Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting. Antiviral Therapy 4(3): 151-156, 1999

Safety and efficacy of kidney transplant biopsy: Tru-Cut needle vs sonographically guided Biopty gun. Ajr. American Journal of Roentgenology 160(2): 325-326, 1993

Evolution of antioxidant defence mechanisms. European Journal of Nutrition 39(2): 53-61, 2000

Abacavir systemic clearance in children is highly influenced by glucuronidation phenotype. Pharmacotherapy 22(10): 1347, 2002

A randomized, open-label, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advanced AIDS patients. Journal of the Medical Association of Thailand 85(5): 590-596, 2002

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2): 118-125, 1996

Amprenavir approved for HIV treatment. American Journal of Health-System Pharmacy 56(11): 1057-1058, 1999

Emergence of crop seedlings in soils associated with bare patches beneath the canopy of the aromatic shrub Artemisia afra. Applied Plant Science 11(2): 35-38, 1997

Dual requirement in yeast DNA mismatch repair for MLH1 and PMS1, two homologs of the bacterial mutL gene. Molecular and Cellular Biology 14(1): 407-415, 1994

Emergence of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 Variants, Viral Sequence Variation, and Disease Progression in Patients Receiving Antiretroviral Chemotherapy. The Journal of Infectious Diseases 177(6): 1506-1513, 1998

Induction when rats respond for liquid-sucrose reinforcement as a function of amount of upcoming work. Psychological Record 56(3): 429-446, 2006